News Breaks |
|
|
| October 12, 2012 |
| 09:16 EDT |  | ARNA | Arena Pharmaceuticals initiates Phase 1 APD811 trial
Arena Pharmaceuticals announced the initiation of dosing in a Phase 1 multiple dose clinical trial of APD811, a novel oral drug candidate discovered by Arena that targets the prostacyclin receptor for the treatment of pulmonary arterial hypertension. The randomized, double-blind and placebo-controlled dose titration trial is planned to enroll up to 30 healthy adult volunteers, and will evaluate the safety, tolerability and pharmacokinetics of multiple-ascending doses of APD811 and the optimal titration schedule. Arena previously evaluated single-ascending doses of APD811 in the initial Phase 1 clinical trial. |
|
|
News For ARNA From The Last 14 Days Check below for free stories on ARNA the last two weeks. |
|
|
| May 22, 2013 |
| 12:08 EDT |  | ARNA | Options with decreasing implied volatility: ARNA SGMO NTAP CBST GDI
|
|
| May 21, 2013 |
| 12:32 EDT | | ARNA | Options with decreasing implied volatility: PXP ARNA BBY OPK CSC
|
|
| May 17, 2013 |
| 11:53 EDT | | ARNA | Options with decreasing implied volatility: SGMO ARNA CSC ENDP
 Subscribe for More Information |
|
| May 15, 2013 |
| 14:03 EDT |  | ARNA | Arena Pharma has positive read through from Eisai forecast, says Piper Jaffray
Subscribe for More Information |
|
| 06:19 EDT | | ARNA | Arena Pharmaceuticals implied volatility at lower end of index mean range
Subscribe for More Information |
|
| May 8, 2013 |
| 05:52 EDT | | ARNA | Stocks with implied volatility movement; ARNA ANR
Stocks with implied volatility movement; Arena Pharmaceuticals (ARNA), Alpha Natural (ANR) according to IVolatility. |
|
|
|
|
|
